Biotech Hunter
Biotech Hunter
Home
Companies
Trials
People
Search
Home
/
Trials
/
NCT00237887
NCT00237887
View on ClinicalTrials.gov
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
PHASE3
Completed
INTERVENTIONAL
Enrollment
1,212
Participants
Timeline
Start Date
December 31, 2004
Conditions
Psoriasis
Interventions
DRUG
adalimumab
Sponsors
Lead Sponsor
Abbott
All Listed Sponsors
lead
Abbott
INDUSTRY
NCT00237887 - Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis | Biotech Hunter | Biotech Hunter